GEP20053494B - Crystalline Therapeutic Agent - Google Patents

Crystalline Therapeutic Agent

Info

Publication number
GEP20053494B
GEP20053494B GE5062A GEAP2001005062A GEP20053494B GE P20053494 B GEP20053494 B GE P20053494B GE 5062 A GE5062 A GE 5062A GE AP2001005062 A GEAP2001005062 A GE AP2001005062A GE P20053494 B GEP20053494 B GE P20053494B
Authority
GE
Georgia
Prior art keywords
therapeutic agent
crystalline therapeutic
crystalline
ethylpipera
pharmacochemistry
Prior art date
Application number
GE5062A
Other languages
English (en)
Inventor
Laurence James Harris
Richard Anthony Storey
Albert Shaw Wood
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0018656A external-priority patent/GB0018656D0/en
Priority claimed from GB0106464A external-priority patent/GB0106464D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of GEP20053494B publication Critical patent/GEP20053494B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
GE5062A 2000-07-28 2001-07-18 Crystalline Therapeutic Agent GEP20053494B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0018656A GB0018656D0 (en) 2000-07-28 2000-07-28 Pharmaceutically active compounds
GB0106464A GB0106464D0 (en) 2001-03-15 2001-03-15 Crystalline therapeutic agent

Publications (1)

Publication Number Publication Date
GEP20053494B true GEP20053494B (en) 2005-04-25

Family

ID=26244756

Family Applications (1)

Application Number Title Priority Date Filing Date
GE5062A GEP20053494B (en) 2000-07-28 2001-07-18 Crystalline Therapeutic Agent

Country Status (45)

Country Link
EP (1) EP1305314B1 (enExample)
JP (1) JP2004505087A (enExample)
KR (1) KR100457937B1 (enExample)
CN (1) CN1207297C (enExample)
AP (1) AP1400A (enExample)
AR (1) AR032628A1 (enExample)
AT (1) ATE286901T1 (enExample)
AU (2) AU2001272690B2 (enExample)
BG (1) BG107266A (enExample)
BR (1) BR0112734A (enExample)
CA (1) CA2417264C (enExample)
CZ (1) CZ2003126A3 (enExample)
DE (1) DE60108398T2 (enExample)
DO (1) DOP2001000217A (enExample)
DZ (1) DZ3364A1 (enExample)
EA (1) EA004681B1 (enExample)
EC (1) ECSP034454A (enExample)
EE (1) EE200300045A (enExample)
ES (1) ES2231521T3 (enExample)
GE (1) GEP20053494B (enExample)
HR (1) HRP20030061A2 (enExample)
HU (1) HUP0302982A3 (enExample)
IL (1) IL153226A0 (enExample)
IN (1) IN2002MU01649A (enExample)
IS (1) IS6626A (enExample)
MA (1) MA26931A1 (enExample)
MX (1) MX233602B (enExample)
MY (1) MY117831A (enExample)
NO (1) NO324220B1 (enExample)
NZ (1) NZ523226A (enExample)
OA (1) OA12337A (enExample)
PA (1) PA8523501A1 (enExample)
PE (1) PE20020277A1 (enExample)
PH (1) PH12001001922B1 (enExample)
PL (1) PL365133A1 (enExample)
PT (1) PT1305314E (enExample)
SK (1) SK572003A3 (enExample)
SV (1) SV2001000570A (enExample)
TN (1) TNSN01112A1 (enExample)
TW (1) TWI285643B (enExample)
UA (1) UA72631C2 (enExample)
UY (1) UY26854A1 (enExample)
WO (1) WO2002010171A1 (enExample)
YU (1) YU4703A (enExample)
ZA (1) ZA200301457B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004072079A1 (en) * 2003-02-11 2004-08-26 Pfizer Limited Hydrated and anhydrous sildenafil hemi-citrate compound
EA008596B1 (ru) 2003-04-29 2007-06-29 Пфайзер Инк. 5,7-ДИАМИНОПИРАЗОЛО[4,3-d]ПИРИМИДИНЫ, ПОЛЕЗНЫЕ ПРИ ЛЕЧЕНИИ ГИПЕРТЕНЗИИ
US7572799B2 (en) 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
DK1742950T3 (da) 2004-04-07 2009-03-16 Pfizer Ltd Pyrazolo-[4,3-D]-pyrimidiner
CA2608018C (en) 2005-05-12 2010-07-13 Pfizer Inc. Anhydrous crystalline forms of n-[1-(2-ethoxyethyl)-5-(n-ethyl-n-methylamino)-7-(4-methylpyridin-2-yl-amino)-1h-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1371647B1 (en) * 1998-04-20 2005-07-13 Pfizer Inc. Pyridine-3-carboxylic acid derivatives and their use as intermediates
TWI265925B (en) * 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them

Also Published As

Publication number Publication date
AU7269001A (en) 2002-02-13
DE60108398T2 (de) 2005-12-22
MX233602B (es) 2006-01-10
OA12337A (en) 2006-05-15
MA26931A1 (fr) 2004-12-20
MY117831A (en) 2004-08-30
PL365133A1 (en) 2004-12-27
YU4703A (sh) 2006-01-16
IL153226A0 (en) 2003-07-06
HRP20030061A2 (en) 2003-04-30
MXPA03000856A (es) 2003-06-06
KR100457937B1 (ko) 2004-11-20
AR032628A1 (es) 2003-11-19
BG107266A (bg) 2003-07-31
TWI285643B (en) 2007-08-21
ES2231521T3 (es) 2005-05-16
NZ523226A (en) 2003-07-25
HUP0302982A3 (en) 2005-01-28
DOP2001000217A (es) 2002-10-30
NO324220B1 (no) 2007-09-10
UA72631C2 (uk) 2005-03-15
KR20030016430A (ko) 2003-02-26
EE200300045A (et) 2004-12-15
CZ2003126A3 (cs) 2004-02-18
IN2002MU01649A (enExample) 2004-12-11
PH12001001922B1 (en) 2006-11-21
UY26854A1 (es) 2002-02-28
AP1400A (en) 2005-04-28
JP2004505087A (ja) 2004-02-19
DE60108398D1 (de) 2005-02-17
HUP0302982A2 (hu) 2003-12-29
EP1305314B1 (en) 2005-01-12
EP1305314A1 (en) 2003-05-02
WO2002010171A1 (en) 2002-02-07
ECSP034454A (es) 2003-03-10
EA200300079A1 (ru) 2003-06-26
SV2001000570A (es) 2002-09-03
CN1207297C (zh) 2005-06-22
AU2001272690B2 (en) 2005-12-08
BR0112734A (pt) 2004-08-10
EA004681B1 (ru) 2004-06-24
SK572003A3 (en) 2004-05-04
NO20030416D0 (no) 2003-01-27
DZ3364A1 (fr) 2002-02-07
NO20030416L (no) 2003-02-05
IS6626A (is) 2002-11-18
HK1055954A1 (en) 2004-01-30
PT1305314E (pt) 2005-04-29
AP2001002234A0 (en) 2001-09-30
PA8523501A1 (es) 2002-10-24
CN1444585A (zh) 2003-09-24
PE20020277A1 (es) 2002-05-11
ATE286901T1 (de) 2005-01-15
TNSN01112A1 (fr) 2005-11-10
CA2417264C (en) 2007-06-12
ZA200301457B (en) 2004-04-28
CA2417264A1 (en) 2002-02-07

Similar Documents

Publication Publication Date Title
MX9702307A (es) Pirrolo (2,3-d)pirimidinas y su uso.
MY132106A (en) New pyridazin-3(2h)-one derivatives
HUP0104605A3 (en) Quinoline and quinoxaline compounds as pdgf-receptor and/or lck tyrosine kinase inhibitors, medicaments containing them and their use
AU7931301A (en) Method of using diketopiperazines and composition containing them
HUP0400908A3 (en) Pyrazole compounds useful as protein kinase inhibitors, their use and pharmaceutical compositions containing them
HUP0400692A3 (en) Substituted 7h-pyrrolo[2,3-d]pyrimidine derivatives, their use and pharmaceutical compositions containing them
PL377239A1 (pl) Nowe amino-podstawione pochodne dihydropirymido [4,5-d]-pirymidynonu, ich wytwarzanie i zastosowanie jako środków framaceutycznych
AU2002312933A1 (en) CDK inhibiting pyrimidines, production thereof and their use as medicaments
HUP0402113A3 (en) 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity, preparation and use thereof
AU2001251063A1 (en) 3-cyanoquinolines,3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
GB0124933D0 (en) Chemical compounds
IL165392A (en) Use of vegfr modulator materials to prepare and protect liver growth drugs, products and kits that include them
AU2002251546A1 (en) Pyrazolo[1,5-A]pyridines and medicines containing the same
MXPA03010761A (es) Combinaciones farmaceuticas.
AU2003298937A1 (en) Heterocyclic compounds, methods of making them and their use in therapy
CA2328280A1 (en) Thienopyrimidines
AU2002366736A1 (en) Masked phosphate containing nucleoside derivatives and their use as antivirals
YU4703A (sh) Kristalni terapeutski agens
AU2003219900A1 (en) Antigene locks and therapeutic uses thereof
IL176523A0 (en) Ascorbic acid compounds, methods of synthesis and application use thereof
AU2002246983A1 (en) 1,2-disubstituted cyclic inhibitors of matrix metallorproteases and tnf-alpha
IL162524A0 (en) Derivatives of (pyridin-3-yl)-1-azabicycloÄ3.2.1Ü octane, their preparation and their terapeutic application
PL373247A1 (en) Method for treating tumors by the administration of tegafur, uracil, folinic acid, and cyclophosphamide
MXPA03003198A (es) 3,4-dihidro-pirido [1,2-a]pirimidinas sustituidas.
AU2002361989A1 (en) N,n'-disubstituted piperazine compounds and the use of the same as analgesics